Cancer drug price cap: Why India needs a bigger plan

Why in the News

The Centre has told the Supreme Court that trade margins on specified non-scheduled cancer drugs will be capped at 30%. The Court has asked why similar scrutiny should not extend to other medicines and medical products. That raises whether regulating one category at a time can fix excessive margins.

What is a trade margin cap on cancer drugs?

1. Trade margin: This is the gap between a product’s price on entering the supply chain and the price a patient pays. A cap limits it, like a ceiling on a shop’s markup.
2. Non-scheduled drugs: These are medicines outside the list whose ceiling prices the government fixes directly.
3. Why it was introduced: In a welfare state, the government must keep healthcare accessible and affordable. When the price gap becomes hard to justify, the government cannot remain a passive observer.
4. How it will work: An expert committee will identify the medicines to be covered. The National Pharmaceutical Pricing Authority (NPPA), the national drug price regulator, will then examine its recommendations.
5. The takeaway: The cap is a useful first step on cancer drug prices, but it leaves margins on other medicines and products unexamined.

Why is a one-category approach not enough?

1. Three open questions: The debate asks whether the exercise is comprehensive enough, whether it rests on adequate evidence, and whether it can work across India’s large and varied healthcare market.
2. Shifting distortions: Regulating one category at a time can move distortions from one part of the market to another.
3. Uncertainty and enforcement: A fragmented approach creates uncertainty for suppliers and makes enforcement needlessly difficult.
4. Wider review: If excessive margins are the problem, India should examine them comprehensively, not drug class by drug class.

Why must evidence come before the price cap?

1. Same drug, different cost: The same medicine can cost different amounts to administer at two hospitals in the same city. The difference arises from:
   • the patient’s condition and the complexity of treatment;
   • the clinical team’s expertise and the infrastructure available;
   • infection-control needs, monitoring levels and standby emergency support.
2. Procurement price is partial: A routine outpatient medicine cannot be equated with a complex therapy given under specialist supervision, so the purchase price tells only part of the story.
3. Margin versus legitimate cost: A robust framework must separate the trade margin from the legitimate cost of storing, handling and safely administering a product.
4. Access effects: Without that distinction, a rule aimed at excessive margins could reduce availability and harm the quality of care.

What does the 2019 pilot teach?

1. Earlier exercise: The 2019 trade margin rationalisation pilot covered 42 selected non-scheduled anti-cancer medicines.
2. Concerns raised since: Consultations have flagged production costs, the viability of smaller manufacturers and the cost of maintaining supplies in remote areas. Answering these concerns can guide the design of future intervention.

Challenges

1. Investment disincentive: Blanket controls that ignore real cost differences could discourage hospitals from expanding infrastructure and adopting new technology.
2. Supply shortages: Margins squeezed below handling costs may leave patients facing shortages or reduced access.
3. Quality and safety: Hospitals may find it harder to maintain safety standards or adopt medical advances.
4. Rising demand: A growing disease burden needs continued investment in healthcare, which rigid caps could choke.

Way Forward

1. Comprehensive review: The government should examine trade margins across medicines, medical devices and consumables using a common, scientifically credible method.
2. Targeted intervention: The common method should identify where intervention is needed and in what form, not apply one formula to every product.
3. Stakeholder consultation: Manufacturers, distributors, hospitals, clinicians, insurers, patient groups and State governments should feed evidence into the framework.
4. Outcome metric: Success should be judged by fairer prices without shortages or poorer care, not by the number of products controlled.

Conclusion

The cancer drug cap answers a real affordability concern, but lasting reform depends on separating unjustified margins from the genuine cost of delivering care. The expert committee’s list, and whether the Centre widens the review as the Court has asked, are the next steps to watch.

Matching Previous Year Question

“No direct PYQ traced in the provided files. Thematic PYQ: [2015, GS2, 12 marks] For achieving the desired objectives, it is necessary to ensure that the regulatory institutions remain independent and autonomous. Discuss in the light of the experiences in recent past.”